These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

279 related articles for article (PubMed ID: 30132210)

  • 1. Pharmacokinetic and Immunological Considerations for Expanding the Therapeutic Window of Next-Generation Antibody-Drug Conjugates.
    Khera E; Thurber GM
    BioDrugs; 2018 Oct; 32(5):465-480. PubMed ID: 30132210
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetic Considerations for Antibody-Drug Conjugates against Cancer.
    Malik P; Phipps C; Edginton A; Blay J
    Pharm Res; 2017 Dec; 34(12):2579-2595. PubMed ID: 28924691
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preclinical Pharmacokinetic Considerations for the Development of Antibody Drug Conjugates.
    Kamath AV; Iyer S
    Pharm Res; 2015 Nov; 32(11):3470-9. PubMed ID: 25446773
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antibody-Drug Conjugates: A Review on the Epitome of Targeted Anti- Cancer Therapy.
    Hasan M; Alam S; Poddar SK
    Curr Clin Pharmacol; 2018; 13(4):236-251. PubMed ID: 30073930
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Practical considerations for the pharmacokinetic and immunogenic assessment of antibody-drug conjugates.
    Sauerborn M; van Dongen W
    BioDrugs; 2014 Aug; 28(4):383-91. PubMed ID: 24842227
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antibody-Drug Conjugates as Cancer Therapeutics: Past, Present, and Future.
    Vezina HE; Cotreau M; Han TH; Gupta M
    J Clin Pharmacol; 2017 Oct; 57 Suppl 10():S11-S25. PubMed ID: 28921650
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Latest Research and Development into the Antibody-Drug Conjugate, [fam-] Trastuzumab Deruxtecan (DS-8201a), for HER2 Cancer Therapy.
    Nakada T; Sugihara K; Jikoh T; Abe Y; Agatsuma T
    Chem Pharm Bull (Tokyo); 2019; 67(3):173-185. PubMed ID: 30827997
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prospects and progress of antibody-drug conjugates in solid tumor therapies.
    Govindan SV; Sharkey RM; Goldenberg DM
    Expert Opin Biol Ther; 2016 Jul; 16(7):883-93. PubMed ID: 27045979
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An Agent-Based Systems Pharmacology Model of the Antibody-Drug Conjugate Kadcyla to Predict Efficacy of Different Dosing Regimens.
    Menezes B; Cilliers C; Wessler T; Thurber GM; Linderman JJ
    AAPS J; 2020 Jan; 22(2):29. PubMed ID: 31942650
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rational design, biophysical and biological characterization of site-specific antibody-tubulysin conjugates with improved stability, efficacy and pharmacokinetics.
    Thompson P; Fleming R; Bezabeh B; Huang F; Mao S; Chen C; Harper J; Zhong H; Gao X; Yu XQ; Hinrichs MJ; Reed M; Kamal A; Strout P; Cho S; Woods R; Hollingsworth RE; Dixit R; Wu H; Gao C; Dimasi N
    J Control Release; 2016 Aug; 236():100-16. PubMed ID: 27327768
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Systems Pharmacology Model for Drug Delivery to Solid Tumors by Antibody-Drug Conjugates: Implications for Bystander Effects.
    Burton JK; Bottino D; Secomb TW
    AAPS J; 2019 Dec; 22(1):12. PubMed ID: 31828446
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Chemical Design and Synthesis of Linkers Used in Antibody Drug Conjugates.
    Frigerio M; Kyle AF
    Curr Top Med Chem; 2017; 17(32):3393-3424. PubMed ID: 29357801
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Considerations for the nonclinical safety evaluation of antibody drug conjugates for oncology.
    Roberts SA; Andrews PA; Blanset D; Flagella KM; Gorovits B; Lynch CM; Martin PL; Kramer-Stickland K; Thibault S; Warner G
    Regul Toxicol Pharmacol; 2013 Dec; 67(3):382-91. PubMed ID: 24012707
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antibody-Drug Conjugate-Based Therapeutics: State of the Science.
    Birrer MJ; Moore KN; Betella I; Bates RC
    J Natl Cancer Inst; 2019 Jun; 111(6):538-549. PubMed ID: 30859213
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antibody-targeted drugs and drug resistance--challenges and solutions.
    Shefet-Carasso L; Benhar I
    Drug Resist Updat; 2015 Jan; 18():36-46. PubMed ID: 25476546
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antibody Drug Conjugates: Preclinical Considerations.
    Bornstein GG
    AAPS J; 2015 May; 17(3):525-34. PubMed ID: 25724883
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The next generation of antibody drug conjugates.
    Mack F; Ritchie M; Sapra P
    Semin Oncol; 2014 Oct; 41(5):637-52. PubMed ID: 25440608
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Capturing the Magic Bullet: Pharmacokinetic Principles and Modeling of Antibody-Drug Conjugates.
    Zuo P
    AAPS J; 2020 Aug; 22(5):105. PubMed ID: 32767003
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Optimizing Solid Tumor Treatment with Antibody-drug Conjugates Using Agent-Based Modeling: Considering the Role of a Carrier Dose and Payload Class.
    Calopiz MC; Linderman JJ; Thurber GM
    Pharm Res; 2024 Jun; 41(6):1109-1120. PubMed ID: 38806889
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antibody-drug conjugates: an emerging modality for the treatment of cancer.
    Leal M; Sapra P; Hurvitz SA; Senter P; Wahl A; Schutten M; Shah DK; Haddish-Berhane N; Kabbarah O
    Ann N Y Acad Sci; 2014 Aug; 1321():41-54. PubMed ID: 25123209
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.